New keytruda copycat tested for melanoma prevention
NCT ID NCT07475572
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests AVT32-DRL_PB, a biosimilar (copy) of the cancer drug Keytruda, in 120 people with stage IIB/C or III melanoma whose tumors were fully removed. Half get the biosimilar, half get Keytruda, every 3 weeks. The main goal is to see if drug levels in the blood are similar, not yet to prove it works as well.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AVT32-DRL_PB (a biosimilar to the cancer drug Keytruda)
- What this could lead to
- If successful, this could provide a more affordable alternative to Keytruda for preventing melanoma recurrence after surgery.
- What could go wrong
- This is an early Phase 1 trial focused on comparing drug levels in the blood, not yet on long-term outcomes. The biosimilar may not work as well or have different side effects than Keytruda.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can new drug cocktails reawaken the immune system against melanoma?
- Could a Six-Month exercise and diet plan shield muscle during melanoma treatment?
- E-Learning could sharpen Doctors' eye for skin cancer
- Quitting before the knife: which Stop-Smoking aid works best for cancer patients?
- Can a new drug tame advanced solid tumors?
- Can a One-Two punch of immune boosters revive cancer treatment?